Payment overview · 2025
General Payments
$432.57
24 reported records · 12 companies
Healthcare provider profile · identity verified
Kyle K Nelson, DO
Allopathic & Osteopathic Physicians|Family Medicine · ANDERSON, SC · NPI 1316998180
Verified facts
What the public records show
CMS Open Payments records show Kyle K Nelson, DO received $432.57 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.41 | 14.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.20 | 13.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.50 | 13.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.32 | 11.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.71 | 10.8% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $34.23 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.33 | 7.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.68 | 4.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.39 | 4.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.29 | 4.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.64 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.87 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.57 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $70.30 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.31 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Spectra WaveWriter Normalized: spectra wavewriter |
Device | Boston Scientific Corporation | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 596 | 150 |
| Losartan Potassium | Losartan Potassium | 491 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 142 |
| Omeprazole | Omeprazole | 431 | 130 |
| Lisinopril | Lisinopril | 308 | 90 |
| Famotidine | Famotidine | 287 | 97 |
| Metformin Hcl Er | Metformin Hcl | 264 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 78 |
| Meloxicam | Meloxicam | 259 | 93 |
| Metformin Hcl | Metformin Hcl | 257 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 84 |
| Gabapentin | Gabapentin | 230 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 72 |
| Glipizide Er | Glipizide | 220 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 214 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 213 | 53 |
| Trazodone Hcl | Trazodone Hcl | 211 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 88 |
| Carvedilol | Carvedilol | 209 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 77 |
| Chlorthalidone | Chlorthalidone | 201 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 67 |
| Mirtazapine | Mirtazapine | 185 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 182 | 53 |
| Simvastatin | Simvastatin | 171 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 52 |
| Allopurinol | Allopurinol | 159 | 43 |
| Furosemide | Furosemide | 154 | 57 |
| Lorazepam | Lorazepam | 134 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 42 |
| Tramadol Hcl | Tramadol Hcl | 122 | 26 |
| Jardiance | Empagliflozin | 121 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 31 |
| Clonazepam | Clonazepam | 114 | 20 |
| Valsartan | Valsartan | 113 | 29 |
| Montelukast Sodium | Montelukast Sodium | 110 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 21 |
| Mounjaro | Tirzepatide | 98 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 27 |
| Ezetimibe | Ezetimibe | 89 | 28 |
| Trulicity | Dulaglutide | 88 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 23 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 48 |
| Alendronate Sodium | Alendronate Sodium | 80 | 23 |
| Celecoxib | Celecoxib | 79 | 25 |
| Prednisone | Prednisone | 78 | 69 |
| Ozempic | Semaglutide | 69 | 17 |
| Farxiga | Dapagliflozin Propanediol | 68 | 15 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Alprazolam | Alprazolam | 65 | 13 |
| Telmisartan | Telmisartan | 65 | 23 |
| Synthroid | Levothyroxine Sodium | 64 | 18 |
| Enalapril Maleate | Enalapril Maleate | 58 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Baclofen | Baclofen | 47 | 15 |
| Pregabalin | Pregabalin | 47 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 45 |
| Eliquis | Apixaban | 45 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 23 |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Colchicine | Colchicine | 39 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 35 |
| Atenolol | Atenolol | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | 11 |
| Azelastine Hcl | Azelastine Hcl | 37 | 12 |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 14 |
| Myrbetriq | Mirabegron | 36 | 12 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Dutasteride | Dutasteride | 33 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 12 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 30 |
| Finasteride | Finasteride | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Estradiol | Estradiol | 29 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Nystatin | Nystatin | 26 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Primidone | Primidone | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Naproxen | Naproxen | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Cephalexin | Cephalexin | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.57 · 24 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SAPIEN 3 Ultra RESILIA, Spectra WaveWriter, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error